<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0629E426-16BD-4CCD-B885-6826BA69C2C1"><gtr:id>0629E426-16BD-4CCD-B885-6826BA69C2C1</gtr:id><gtr:name>Japan Breast Cancer Research Group (JBCRG)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Molecular. Genetics &amp; Pop Health</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0629E426-16BD-4CCD-B885-6826BA69C2C1"><gtr:id>0629E426-16BD-4CCD-B885-6826BA69C2C1</gtr:id><gtr:name>Japan Breast Cancer Research Group (JBCRG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D93DF180-582A-47D7-95D8-CEEBE2D1B60F"><gtr:id>D93DF180-582A-47D7-95D8-CEEBE2D1B60F</gtr:id><gtr:firstName>Niall</gtr:firstName><gtr:surname>Anderson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/484F371D-5493-4DB9-8046-0116A8F1BB00"><gtr:id>484F371D-5493-4DB9-8046-0116A8F1BB00</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Denvir</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B02BF840-72D6-4252-BEE8-E531697E7543"><gtr:id>B02BF840-72D6-4252-BEE8-E531697E7543</gtr:id><gtr:firstName>Geraldine Anne</gtr:firstName><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/310B8059-BF02-45AB-9E41-DDE7CF4A9F8D"><gtr:id>310B8059-BF02-45AB-9E41-DDE7CF4A9F8D</gtr:id><gtr:firstName>Edwin</gtr:firstName><gtr:otherNames>George</gtr:otherNames><gtr:surname>Aird</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3B051FAD-4708-4214-88E8-E51A996157C1"><gtr:id>3B051FAD-4708-4214-88E8-E51A996157C1</gtr:id><gtr:firstName>M</gtr:firstName><gtr:surname>Dixon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/85278E78-0240-43F5-8B0C-892E15CCE982"><gtr:id>85278E78-0240-43F5-8B0C-892E15CCE982</gtr:id><gtr:firstName>Theresa</gtr:firstName><gtr:surname>McDonagh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A53A7F4C-8A8F-4D36-A7B3-2064FB8F1A5C"><gtr:id>A53A7F4C-8A8F-4D36-A7B3-2064FB8F1A5C</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Bartlett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/283D09F8-9E34-4A60-B146-845FF4EAADF8"><gtr:id>283D09F8-9E34-4A60-B146-845FF4EAADF8</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Canney</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77CE5CE3-9C7F-4C66-A07D-EAFAFDFE737E"><gtr:id>77CE5CE3-9C7F-4C66-A07D-EAFAFDFE737E</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Price</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E5014380-1EFF-463C-A091-47CC81A81434"><gtr:id>E5014380-1EFF-463C-A091-47CC81A81434</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Cairns</gtr:surname><gtr:orcidId>0000-0001-6442-0440</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6085B6D0-9206-4E47-913C-67A90479C2D3"><gtr:id>6085B6D0-9206-4E47-913C-67A90479C2D3</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Sainsbury</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DB09A3ED-2068-4491-8C53-6830B2CDF9C1"><gtr:id>DB09A3ED-2068-4491-8C53-6830B2CDF9C1</gtr:id><gtr:firstName>Penelope</gtr:firstName><gtr:surname>Hopwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5616E0EF-6C13-4DEC-A430-FD94E45534C7"><gtr:id>5616E0EF-6C13-4DEC-A430-FD94E45534C7</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Prescott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BC3CCFC6-EE63-4776-8616-50178DF65BA0"><gtr:id>BC3CCFC6-EE63-4776-8616-50178DF65BA0</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:surname>Foster</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/265A919F-C609-4936-B202-8D066C39B258"><gtr:id>265A919F-C609-4936-B202-8D066C39B258</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/082383DC-9D37-48E1-B780-07842C614E95"><gtr:id>082383DC-9D37-48E1-B780-07842C614E95</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Kunkler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EA41A237-A451-4061-8E91-209756B2363F"><gtr:id>EA41A237-A451-4061-8E91-209756B2363F</gtr:id><gtr:firstName>Angela</gtr:firstName><gtr:surname>Bowman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400170"><gtr:id>D0ACAB67-296B-4C1B-903B-BEBF21796428</gtr:id><gtr:title>SUPREMO</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400170</gtr:grantReference><gtr:abstractText>The results of the trial will be made publicaly available.</gtr:abstractText><gtr:technicalSummary>SUPREMO Abstract

The role of adjuvant postmastectomy radiotherapy (PMRT) in women with intermediate risk breast cancer is uncertain. SUPREMO is a phase III randomised international clinical trial assessing the role of PMRT and, if appropriate, systemic therapy in women (pT1,NI,M0 or pT1,NI,MO) with 1-3 involved nodes or node negative with other risk factors (grade 3 and/or lymphovascular invasion). The primary end point is overall survival.Secondary endpoints are disease free survival, acute and late morbidity, quality of life, molecular markers of radiation sensitivity and cost effectiveness.Patients will be randomised to PMRT or no PMRT.Target accrual is 3700 patients over 4 years, allowing 5% for attrition, with 5 years of follow up. The sample size is sufficient to detect a statistically significant difference (p 0.05) between 5 year survival rates of 75% and 79%. The trial is underpinned by a quality assurance programme.
 A biological substudy (TRANS-SUPREMO) aims to define a molecular signature for chest wall relapse, identifying which patients may or may not benefit from PMRT. Molecular profiles of relapse identified from the Scottish Conservation trial (Forrest et al,1996) will be used to identify key molecular/biochemical pathways relevant to relapse and radiosensitivity in SUPREMO.Tissue microarrays will be collected from paraffin blocks from mastectomy specimens from all patients.
 A Quality of Life substudy of 800 UK patients, the primary endpoints are fatigue (EORTC,QLQ-C30), physical functioning (QLQ-C30), chest wall, shoulder and arm symptoms (EORTC BR23) and the Body Image Scale (BIS).Descriptive data will be collected for role functioning,social and sexual functioning, pain, nausea and vomiting, anxiety and depression (HADS).
 In a cardiac substudy the role of serum brain natriuretic peptide (BNP) will be studied in assessing the impact of chemotherapy (CT) and PMRT on treatment induced cardiac damage. BNP levels with be measured before CT/RT,post CT, post RT and at 1 and 5 years.
 In a health economic substudy the cost effectiveness of PMRT will be measured in all UK patients.Usage of community and health service resources will be collected at follow up supplemented by review of hospital records.The primary analysis will determine the extent to which the costs between the two arms of the trial differ. A secondary analysis will model the determinants of difference in cost between individual patients.Cost per life year saved will be calculated as the measure of cost effectiveness.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-11-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2121525</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Breast International Group</gtr:description><gtr:id>0A2C97E9-478D-4C0C-92B4-0BD344997FDC</gtr:id><gtr:impact>The EORTC has contributed 185 patients to the trial.</gtr:impact><gtr:outcomeId>QX8STBASsUb-1</gtr:outcomeId><gtr:partnerContribution>The EORTC has contributed significantly to the trial accrual and two of its members have been active members of the Trial Management Group</gtr:partnerContribution><gtr:piContribution>We established research partnership with the EORTC Breast Group and obtained their agreement and contract to contribute approximately one third of the planned target accrual.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Japan Breast Cancer Research Group (JBCRG)</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Japanese Breast Trials Group</gtr:department><gtr:description>Japan</gtr:description><gtr:id>F3FFBC73-250E-40B5-AD24-CA27DA75E853</gtr:id><gtr:impact>Japan has contributed 6 patients to the trial.</gtr:impact><gtr:outcomeId>dFKHoN2bGCR-1</gtr:outcomeId><gtr:partnerContribution>The Japanese Breast Trials Group has contributed 5 patients to the trial.</gtr:partnerContribution><gtr:piContribution>Professor Kunkler visited the Kyoto Breast Consensus Conference on Breast Cancer in March 2009 and met with clinical investigators from 4 participating centres in Japan who agreed to participate in the trial and international contracts were established by ISD and the University of Edinburgh.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Inaugural lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>68E01CBB-5469-421B-BABF-ADDA3F8ECC1F</gtr:id><gtr:impact>Approximately 150 people attended this lecture which sparked questions from members of the public.

NA</gtr:impact><gtr:outcomeId>XGFBvwoJeuZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>281128</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EORTC</gtr:description><gtr:end>2023-03-02</gtr:end><gtr:fundingOrg>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:fundingOrg><gtr:id>7EFA55BA-F08A-492F-8671-DB62271DE0C5</gtr:id><gtr:outcomeId>Rj16aagEBAp0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BIG</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6CFDAAF9-9E74-4C48-AD82-D992E7739590</gtr:id><gtr:impact>Professor Kunkler was asked to chair a task force obn the development of breast cancer trials in developing countries.</gtr:impact><gtr:outcomeId>LcRW6nT1iAF</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7C5D1CCA-3F08-4D5D-8A95-7410622FB70C</gtr:id><gtr:title>Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: the MRC/EORTC SUPREMO trial.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b638c466c91184b083a0539110538328"><gtr:id>b638c466c91184b083a0539110538328</gtr:id><gtr:otherNames>Kunkler IH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>EgjxExGNKFy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30FA5518-4E9E-4ACB-A133-393159D3CDE7</gtr:id><gtr:title>Early Breast Cancer - From Screening to Multidisciplinary Management, Third Edition</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75f0a0a27148568b32b045cc8cf3eff5"><gtr:id>75f0a0a27148568b32b045cc8cf3eff5</gtr:id><gtr:otherNames>Kunkler I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-1841843841</gtr:isbn><gtr:outcomeId>H9e7V3Q5Ld4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2E7304C-C443-40EB-B637-30E0458A0125</gtr:id><gtr:title>Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research : BCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33bc6e001ed42152a5afd2aefb93c68a"><gtr:id>33bc6e001ed42152a5afd2aefb93c68a</gtr:id><gtr:otherNames>Eccles SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1465-5411</gtr:issn><gtr:outcomeId>543bcb241f3945.42547663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB8EFE1E-D63A-426C-9AD3-D753E423551C</gtr:id><gtr:title>Post mastectomy radiotherapy in one to three lymph node positive breast cancer.</gtr:title><gtr:parentPublicationTitle>Acta oncologica (Stockholm, Sweden)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3647623177a9fdfffee19cae0657359a"><gtr:id>3647623177a9fdfffee19cae0657359a</gtr:id><gtr:otherNames>Munshi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0284-186X</gtr:issn><gtr:outcomeId>QtnvPdJYaJP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0A7E6FA-C395-48E3-AEDD-427513E74FEB</gtr:id><gtr:title>Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA).</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fda153517f65dfe488a3d21de804e11"><gtr:id>3fda153517f65dfe488a3d21de804e11</gtr:id><gtr:otherNames>Biganzoli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>kEBhPxeRv4c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18159C12-D724-42F1-B5F0-BC0B1D82F9EE</gtr:id><gtr:title>New strategies for targeting the hypoxic tumour microenvironment in breast cancer.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9f6b47377a301329abec4c2244578aa"><gtr:id>a9f6b47377a301329abec4c2244578aa</gtr:id><gtr:otherNames>Ward C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>k4Uu2u6881o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A53DE50-9038-4C96-B3FE-A76C5F2A7600</gtr:id><gtr:title>Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b638c466c91184b083a0539110538328"><gtr:id>b638c466c91184b083a0539110538328</gtr:id><gtr:otherNames>Kunkler IH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>543bcb6a96e293.03565403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>498F200C-994B-48BE-A364-5504B717B314</gtr:id><gtr:title>Postmastectomy radiotherapy: will the selective use of postmastectomy radiotherapy study end the debate?</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0c30963a67d5cddd1a7a3a82d8f5676"><gtr:id>a0c30963a67d5cddd1a7a3a82d8f5676</gtr:id><gtr:otherNames>Russell NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>WMRpvnMHrBz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D9682C5-8384-4BE5-B1EE-409019E4FF96</gtr:id><gtr:title>The treatment of early breast cancer in women over the age of 70.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b671ca4cf25177b40ab31d25a293c9c"><gtr:id>3b671ca4cf25177b40ab31d25a293c9c</gtr:id><gtr:otherNames>Ring A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>AFEGbtUo6sZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCF65E79-3BE5-4BDA-8D5C-46B5FBEAD9D8</gtr:id><gtr:title>Breast Surgery : A Companion to Specialist Surgical Practice</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e3e905bf16e1a629e4b2e02fb46f2f"><gtr:id>e7e3e905bf16e1a629e4b2e02fb46f2f</gtr:id><gtr:otherNames>Ian Kunkler</gtr:otherNames></gtr:author></gtr:authors><gtr:isbn>978-0-7020-3012-3</gtr:isbn><gtr:outcomeId>U69kR8WHmoQ</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400170</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>